ES2141744T3 - Azaquinoxalinas, procedimiento para su preparacion y su empleo. - Google Patents

Azaquinoxalinas, procedimiento para su preparacion y su empleo.

Info

Publication number
ES2141744T3
ES2141744T3 ES93114934T ES93114934T ES2141744T3 ES 2141744 T3 ES2141744 T3 ES 2141744T3 ES 93114934 T ES93114934 T ES 93114934T ES 93114934 T ES93114934 T ES 93114934T ES 2141744 T3 ES2141744 T3 ES 2141744T3
Authority
ES
Spain
Prior art keywords
azaquinoxalinas
employment
procedure
preparation
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93114934T
Other languages
English (en)
Inventor
Uta-Maria Billhardt-Troughton
Manfred Dr Rosner
Rudolf Dr Bender
Christoph Dr Meichsner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2141744T3 publication Critical patent/ES2141744T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPUESTOS DE LA FORMULA I, ASI COMO FORMAS TAUTOMERAS DE LA FORMULA (IA) EN LA QUE LOS SUSTITUYENTES R1 HASTA R5 ASI COMO V, W, Y Y Z TIENEN LOS SIGNIFICADOS MENCIONADOS, PRESENTA ACCION CONTRA LOS VIRUS.
ES93114934T 1992-09-26 1993-09-16 Azaquinoxalinas, procedimiento para su preparacion y su empleo. Expired - Lifetime ES2141744T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
ES2141744T3 true ES2141744T3 (es) 2000-04-01

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93114934T Expired - Lifetime ES2141744T3 (es) 1992-09-26 1993-09-16 Azaquinoxalinas, procedimiento para su preparacion y su empleo.

Country Status (20)

Country Link
US (1) US5424311A (es)
EP (1) EP0590428B1 (es)
JP (1) JPH06211855A (es)
KR (1) KR940007035A (es)
AT (1) ATE187724T1 (es)
AU (1) AU664643B2 (es)
CA (1) CA2106882C (es)
CZ (1) CZ9302005A3 (es)
DE (1) DE59309902D1 (es)
DK (1) DK0590428T3 (es)
ES (1) ES2141744T3 (es)
GR (1) GR3032520T3 (es)
HU (1) HUT65302A (es)
IL (1) IL107081A (es)
MX (1) MX9305894A (es)
NZ (1) NZ248762A (es)
PH (1) PH30348A (es)
PT (1) PT590428E (es)
TW (1) TW274550B (es)
ZA (1) ZA937081B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1599395A (en) * 1994-01-03 1995-08-01 Cocensys, Inc. 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
AU773631B2 (en) 1998-07-16 2004-05-27 Aaron Tabor Soy formulations and their use for promoting health
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US7101883B2 (en) 2002-03-18 2006-09-05 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PT1636228E (pt) * 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP2013208B1 (en) * 2006-04-21 2011-06-22 Pfizer Products Inc. Pyridin[3,4-b]pyrazinones
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
AU2007309468B2 (en) * 2006-10-19 2012-05-17 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
ZA200902382B (en) * 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008063455A1 (en) * 2006-11-13 2008-05-29 Hines Richard A Over-the wire exclusion device and system for delivery
US8329695B2 (en) * 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CN102272134B (zh) * 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
MA33053B1 (fr) * 2009-01-23 2012-02-01 Tadeka Pharmaceutical Company Ltd Inhibiteurs de la poly(adp-ribose) polymerase (parp)
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
PL2477987T3 (pl) * 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych
WO2011053518A1 (en) 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
CN102821767A (zh) 2010-02-03 2012-12-12 西格诺药品有限公司 Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
MX357833B (es) 2011-10-19 2018-07-26 Signal Pharm Llc Tratamiento del cancer con inhibidores de tor cinasa.
JP2015501793A (ja) 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類
MX363034B (es) 2011-12-02 2019-03-06 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida de las mismas y metodos de su uso.
EP2817029B1 (en) 2012-02-24 2019-07-10 Signal Pharmaceuticals, LLC Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
AU2014254050B2 (en) 2013-04-17 2018-10-04 Signal Pharmaceuticals, Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
UA119538C2 (uk) 2013-04-17 2019-07-10 Сігнал Фармасьютікалз, Елелсі Лікування злоякісної пухлини дигідропіразинопіразинами
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP2016516818A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びｎ−（３−（５−フルオロ−２−（４−（２−メトキシエトキシ）フェニルアミノ）ピリミジン−４−イルアミノ）フェニル）アクリルアミドを含む組合せ療法
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
US9505764B2 (en) 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN109503591B (zh) 2013-05-29 2022-03-01 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
ES2706527T3 (es) 2014-09-16 2019-03-29 Gilead Sciences Inc Métodos para preparar moduladores de receptores tipo Toll
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CA3067585A1 (en) 2017-06-22 2018-12-27 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
GR72941B (es) * 1978-10-20 1984-01-16 Lilly Co Eli
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
PT509398E (pt) * 1991-04-15 2002-02-28 Aventis Pharma Gmbh Quinoxalinas processo para a sua preparacao e sua utilizacao

Also Published As

Publication number Publication date
TW274550B (es) 1996-04-21
NZ248762A (en) 1996-01-26
MX9305894A (es) 1994-03-31
PT590428E (pt) 2000-04-28
DE59309902D1 (de) 2000-01-20
ATE187724T1 (de) 2000-01-15
GR3032520T3 (en) 2000-05-31
US5424311A (en) 1995-06-13
HUT65302A (en) 1994-05-02
KR940007035A (ko) 1994-04-26
ZA937081B (en) 1994-04-18
JPH06211855A (ja) 1994-08-02
HU9302696D0 (en) 1993-12-28
CZ9302005A3 (en) 1994-04-13
IL107081A (en) 1999-07-14
EP0590428A1 (de) 1994-04-06
IL107081A0 (en) 1993-12-28
PH30348A (en) 1997-04-02
AU4755393A (en) 1994-03-31
DK0590428T3 (da) 2000-05-22
CA2106882C (en) 2007-04-17
AU664643B2 (en) 1995-11-23
EP0590428B1 (de) 1999-12-15
CA2106882A1 (en) 1994-03-27

Similar Documents

Publication Publication Date Title
ES2141744T3 (es) Azaquinoxalinas, procedimiento para su preparacion y su empleo.
ATE50763T1 (de) Tetralin-derivate, ihre herstellung und verwendung.
BG92804A (bg) 4-бензоилизоксазолови производни
ES2194842T3 (es) Derivados de 2,4-dioxo-imidazolidina.
MD4B1 (ro) Remediu erbicid
MX9201760A (es) Quinoxalinas, procedimiento para su preparacion y su empleo.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
DK0519327T3 (da) N-Acyl-S-(2-hydroxyalkyl) -cysteiner, deres fremstilling samt deres anvendelse som mellemprodukter til fremstilling af synt
FI853624A0 (fi) 1-substituerade tetralinderivat, deras framstaellning och anvaendning.
IL69986A (en) Cyclohexane-1,3-dione derivatives,their manufacture and their use as herbicides
DK0579968T3 (da) 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse
ATE163402T1 (de) Substituierte ortho- ethenylphenylessigsäurederivate
BR8203379A (pt) Composicoes herbicidas baseadas em derivados de cloro-aceto-ciclo-alquil-amidas
ATE92070T1 (de) Azachromanderivate.
FI960588A0 (fi) Mikrobisideina käytettäviä tiokarbamoyyliyhdisteitä
IL95608A0 (en) 1-methoxypyrimidinyl-n-nitro-phenyl-1h,1,2,4-triazole-3-sulphonamide derivatives and herbicidal compositions containing the same
ES8703847A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinopirimidina
ES8703855A1 (es) Procedimiento para la obtencion de derivados de sulfonilgua-nidinotriazina
ES2100257T3 (es) Acidos 2-arilpropenoicos y su uso para la preparacion de s-cetoprofeno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590428

Country of ref document: ES